IL2 and acute myeloid leukemia: Initial studies reported complete hematologic remission in 30% of poor‐prognosis acute myeloid leukemia (AML) patients treated with subcutaneous IL‐2 after NK cell infusion50; however, the success of this strategy was limited by the rapid expansion of Treg cells following IL‐2 administration.51, 116